Myriad Genetic

Q2 FY2026 EarningsQ2 FY2026 results missed consensus across all key metrics, with revenue of $190.7M vs. $206.0M expected and a GAAP EPS loss of $0.46 vs. $0.267 expected. The top-line miss was exacerbated by an $11.0M negative revenue adjustment for prior-period tests and a significant 15% decline in revenue per test within the Cancer Care segment. Operating loss widened to $38.9M, far exceeding the projected $1.85M loss, driven by aggressive Sales and Marketing expansion (+16% YoY) despite shrinking revenues. Continued reimbursement pressure and volume declines in the Prenatal segment (-9% YoY) underscore significant fundamental headwinds.